Coloplast's New CEO Draws a Line in the Sand: Chronic Care, U.S. Growth, and a Review of Impact4
When Gavin Wood stepped into the CEO role at Coloplast just over three months ago, investors were told to expect listening before action. In today's Q3 2025/26 call, the listening ended. Wood unveiled his first formal priorities, and while they echo the existing Impact4 strategy in broad strokes, the emphasis is unmistakably different: more deliberate investment in Chronic Care, a bigger push into the U.S., and a willingness to reallocate resources—even if it means questioning the very targets the company committed to a year ago.
A Strategy Under Review
Wood's opening remarks were measured but carried a clear undercurrent of change. “We will be more deliberate about where we invest and more focused in our execution with a clear ambition of accelerating growth and strengthening our market positions.” — Gavin Wood, President and CEO · 2026-08-18 That ambition is not yet reflected in the numbers—organic growth came in at 6% for the quarter, and the full-year guidance of 5-6% stands. But the strategic shadow is longer. When pressed on whether the mid-term 7-8% growth target is still credible, Wood conceded that the assessment is ongoing, and Anders Lonning-Skovgaard echoed: “we are currently assessing a number of things... and then we will conclude when we have the full year announcement in November.” — Anders Lonning-Skovgaard, CFO · 2026-08-18 This is the first time the company has publicly left the door open to a revision this early in the plan.
Chronic Care and the U.S.: The Core of the Pitch
The patient-pegged strategy rests on two pillars: defending and extending the Chronic Care franchise, and capturing a larger share of the world's largest healthcare market. Wood framed the U.S. as the biggest value-creation opportunity, noting that it only accounts for a quarter of group sales but holds the most headroom. “We are seeing strong momentum with high single-digit to double-digit growth across Chronic Care and Interventional Urology.” — Gavin Wood, President and CEO · 2026-08-18 The good start in the U.S. Chronic business is a recurring theme, underpinned by product launches like SenSura Mio and the continued ramp of Titan in Men's Health. Titan Prime, the next-generation penile implant, just received FDA approval and is expected to launch in the coming months—a rare near-term catalyst in a quarter otherwise dominated by delays.
Wound & Tissue Repair: Kerecis and the Inpatient Pivot
The most contested piece of the portfolio remains Biologics, where Kerecis is still digesting the reimbursement reset. The company confirmed that the inpatient setting is growing at double-digit rates, while the outpatient segment remains in flux. Wood was frank about the shift:
The leadership change within Wound & Tissue Repair—Fertram stepping aside into a new advisory role—signals that the company is tightening its operating model here. Anders guided that Kerecis should return to profitable growth around Q2 '26/'27, but the market is likely to demand proof of a durable recovery given the repeated setbacks.The center of gravity in Biologics is going to shift towards hospitals and specialist care settings... This is fortunate for us because this is a market where Kerecis is particularly well positioned.
Investing Through Headwinds
Coloplast's gross margin fell 100bps year-on-year to 67%, pressured by FX, ramp-up costs, and raw material inflation. Management maintained the 5% EBIT growth guidance in constant currencies, but the path is being paved by cost discipline and productivity gains. Wood has promised to free up capacity through productivity improvement and organizational simplification, channeling funds into investment in innovation and commercial execution. The question is whether the reinvestment will be enough to offset structural headwinds like China, where a deliberate inventory pullback temporarily depressed growth by DKK 45 million in Q3.
Intibia, once a key accelerator for Interventional Urology, now faces a delay to launch until '27/'28 due to FDA timing. The company was tight-lipped on details, but the push-out raises doubt about whether the high single-digit growth in urology can be sustained without a major new catalyst. Anders, however, pointed to Uromedica and the upcoming Titan Prime as proof that Men's Health can carry the segment.
The Scepter of Guidance
The most consequential signal from the call is the explicit acknowledgment that the Impact4 strategy may need re-baselining. When Veronika Dubajova challenged whether the strategy has lost its way, Wood responded with a promise of a “broader update” at the full-year announcement. For a company that has historically prided itself on predictable growth, the willingness to entertain a revision is a notable shift in tone. As Anders put it, “we are not planning any bigger M&As towards 2030” — Anders Lonning-Skovgaard, CFO · 2026-08-18—a stance that keeps the balance sheet focused on organic execution but also removes the potential for a transformative acquisition to mask underlying deceleration.
From prior calls, the continuity is clear. In May, Wood said “I'm going to need 90 days to really do this listening tour and learn and start to form some opinions.” — Gavin Wood, President and CEO · 2026-05-12 That 90 days is now up, and the opinions are forming. In February, management had been optimistic about Intibia, with Anders noting “We are expecting to get approval later this year in order to launch the solution in the first 6 months of next financial year.” — Anders Lonning-Skovgaard, CFO · 2026-05-12 Today's push-out underscores how quickly external timelines can shift. The Impact4 strategy was always ambitious; now it is also a question mark.